$TMDX (-0,66 %) | TransMedics Group Q3'24 Earnings Highlights:

🔹 Revenue: $108.8M (Est. $114.99M) 🔴; UP +64% YoY 

🔹 EPS: $0.12 (Est. $0.29) 🔴

🔹 Net Income: $4.2M (Est. $11.7M) 

🔹 Gross Margin: 56% (Est. 62%) 🔴

FY24 Guidance: 

🔹 Revenue: $425M-$445M (Est. $444.4M)😕; Expected growth of +76% to +84% YoY

Q3 Segment Revenue: 

🔹 Net Product Revenue: $65.9M; UP +38% YoY 

🔹 Service Revenue: $42.9M; UP +129% YoY

Operational Metrics: 

🔹 Operating Income: $3.9M; vs $(28.3)M in Q3 2023 

🔹 Operating Expenses: $56.9M; DOWN from $69.0M in Q3 2023 

🔹 R&D Expenses: $14.3M; UP from $11.1M in Q3 2023 

🔹 SG&A Expenses: $42.7M; UP from $30.7M in Q3 2023 

🔹 Cash Balance: $330.1M; DOWN from $362.8M in Q2 2024 

🔹 Total Aircraft Owned: 18 as of September 30th, 2024

CEO Waleed Hassanein's Commentary: 

🔸 "We are proud of our performance year to date and look forward to ending 2024 on a strong note. We continued to make meaningful progress across each of our growth initiatives through the third quarter and maintain our conviction in our growth runway for 2025 and beyond."

Key Operational Highlights: 

🔸 Increased utilization of OCS across all three organs 

🔸 Growth in TransMedics logistics services 

🔸 On track for 10,000 OCS transplant cases per year target by 2028 

🔸 Invested in NOP network expansion